Cat. #157678
RMA.Trh4 Kb KO cells
Cat. #: 157678
Sub-type: Primary
Unit size: 1x10^6 cells / vial
Availability: 3-4 weeks
Organism: Mouse
Tissue: Lymphatic Tissue
Disease: Cancer
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Thorbald Van Hall
Institute: Leiden University and Leiden University Medical Center; Stichting Oncode Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: RMA.Trh4 Kb KO cells
- Cancer: Blood cancer
- Cancers detailed: Mouse Leukemia
- Research fields: Cancer
- Tool sub type: Primary
- Parental cell: RMA
- Organism: Mouse
- Tissue: Lymphatic Tissue
- Disease: Cancer
- Model: Knock-Out
- Description: This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo-antigen selectively presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore can present the Trh4 peptide. Clear T cell recognition can be observed since the irrelevant MHC class I H2-Kb was knocked out.This population acts as a clear control. CRISPR edited RMA cells.
- Production details: Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology
- Biosafety level: 1
- Additional notes: CRISPR edited RMA cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide...
- Recommended controls: RMA.Trh4 Db KO cells
- Cellosaurus id: CVCL_J385
Target Details
- Target: Trh4 Kb KO
Applications
- Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...
Handling
- Format: Frozen
- Growth medium: Suspension cells in DMEM+8% FCS
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.
